Eli Lilly and Company plans to more than double its U.S. manufacturing investment since 2020, with a total commitment of over $50 billion. The company expects to begin building four new domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America.
Lilly’s optimism about its pipeline of therapeutic areas drives its unprecedented commitment to domestic manufacturing. The company aims to create more than 3,000 jobs for highly skilled workers at the new sites, including engineers, scientists, operations personnel, and lab technicians. Additionally, it expects to create nearly 10,000 construction jobs during site development.
The new manufacturing facilities will be built in Research Triangle Park, North Carolina; Lebanon, Indiana; and Indianapolis. Lilly’s investments are expected to bring significant economic benefits to the selected communities, including increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and training opportunities.
Lilly’s total domestic capital expansion commitments from 2020 to 2024 now total $X billion. The company welcomes additional interest from states looking to attract new manufacturing investments. Lilly is a medicine company dedicated to turning science into healing, with a focus on harnessing biotechnology, chemistry, and genetic medicine to solve significant health challenges.
Source: https://investor.lilly.com/news-releases/news-release-details/lilly-plans-more-double-us-manufacturing-investment-2020